Factors affecting shared decision-making concerning menopausal hormone therapy.
hormone replacement therapy
menopausal hormone therapy
menopause
shared decision‐making
Journal
Annals of the New York Academy of Sciences
ISSN: 1749-6632
Titre abrégé: Ann N Y Acad Sci
Pays: United States
ID NLM: 7506858
Informations de publication
Date de publication:
17 Jul 2024
17 Jul 2024
Historique:
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
17
7
2024
Statut:
aheadofprint
Résumé
Menopausal hormone therapy (MHT) is an effective treatment for menopause-related symptoms. Menopause management guidelines recommend a personalized approach to menopause care, including MHT use. Decision-making around menopause care is a complex, iterative process influenced by multiple factors framed by perspectives from both women and healthcare providers (HCPs). This narrative review aims to summarize evidence around factors affecting decision-making regarding menopause-related care. For HCPs, the provision of individualized risk estimates is challenging in practice given the number of potential benefits and risks to consider, and the complexity of the data available, especially within time-limited consultations. Women seeking menopause care have the difficult task of making sense of the benefit versus risk profiles to make choices in line with their decisional needs influenced by sociocultural/economic, educational, demographic, and personal characteristics. The press, social media, and influential celebrities also impact the perception of menopause and decision-making around it. Understanding these factors can lead to improved participation in shared decision-making, satisfaction with the decision and decision-making process, adherence to treatment, reduced decisional regret, efficient use of resources, and ultimately long-term satisfaction with care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Institute for Health and Care Research
ID : ACF-2021-21-001
Organisme : National Institute for Health and Care Research
ID : CS-2018-18-ST2-002
Organisme : National Institute for Health and Care Research
ID : NIHR-RP-2014-05-001
Informations de copyright
© 2024 The Author(s). Annals of the New York Academy of Sciences published by Wiley Periodicals LLC on behalf of The New York Academy of Sciences.
Références
National Institute for Health and Care Excellence (NICE). (2015). Menopause: Diagnosis and management. National Institute for Health and Care Excellence (NICE).
Gracia, C. R., & Freeman, E. W. (2018). Onset of the menopause transition. Obstetrics and Gynecology Clinics of North America, 45, 585–597.
Hill, K. (1996). The demography of menopause. Maturitas, 23, 113–127.
Hickey, M., Szabo, R. A., & Hunter, M. S. (2017). Non‐hormonal treatments for menopausal symptoms. BMJ, 359, j5101. https://doi.org/10.1136/bmj.j5101
Avis, N. E., Crawford, S. L., Greendale, G., Bromberger, J. T., Everson‐Rose, S. A., Gold, E. B., Hess, R., Joffe, H., Kravitz, H. M., Tepper, P. G., & Thurston, R. C. (2015). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 175, 531. .
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020). The British Menopause Society & Women's Health Concern 2020 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health, 26, 181–209.
Baber, R. J., Panay, N., & Fenton, A. (2016). 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric, 19, 109–150.
Armeni, E., Lambrinoudaki, I., Ceausu, I., Depypere, H., Mueck, A., Pérez‐López, F. R., Schouw, Y. T. V. D., Senturk, L. M., Simoncini, T., Stevenson, J. C., Stute, P., & Rees, M. (2016). Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas, 89, 63–72.
(2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29, 767–794.
Salisbury, H. (2019). Helen Salisbury: The 10 minute appointment. BMJ, 365, l2389. https://doi.org/10.1136/bmj.l2389
Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288, 321–333.
Million Women Study Collaborators. (2003). Breast cancer and hormone‐replacement therapy in the Million Women Study. Lancet, 362, 419–427.
(2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291, 1701. .
Committee on Safety of Medicines. (2003). Further advice on safety of HRT: Risk:benefit unfavourable for first‐line use in prevention of osteoporosis. https://www.sehd.scot.nhs.uk/publications/DC20031203HRT.pdf
Mcintosh, J., & Blalock, S. J. (2005). Effects of media coverage of Women's Health Initiative study on attitudes and behavior of women receiving hormone replacement therapy. American Journal of Health‐System Pharmacy, 62, 69–74.
Burkard, T., Moser, M., Rauch, M., Jick, S. S., & Meier, C. R. (2019). Utilization pattern of hormone therapy in UK general practice between 1996 and 2015: A descriptive study. Menopause, 26, 741–749.
Pinkerton, J. V. (2020). Hormone therapy for postmenopausal women. New England Journal of Medicine, 382, 446–455.
Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., Manson, J. E., Stefanick, M. L., Pan, K., Barrington, W., Kuller, L. H., Simon, M. S., Lane, D., Johnson, K. C., Rohan, T. E., Gass, M. L. S., Cauley, J. A., Paskett, E. D., Sattari, M., & Prentice, R. L. (2020). Association of menopausal hormone therapy with breast cancer incidence and mortality during long‐term follow‐up of the Women's Health Initiative randomized clinical trials. JAMA, 324, 369. .
Pan, K., Lavasani, S., Aragaki, A. K., & Chlebowski, R. T. (2022). Estrogen therapy and breast cancer in randomized clinical trials: A narrative review. Menopause, 29, 1086–1092.
Collaborative Group on Hormonal Factors in Breast Cancer. (2019). Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta‐analysis of the worldwide epidemiological evidence. Lancet, 394, 1159–1168.
Fournier, A., Berrino, F., & Clavel‐Chapelon, F. (2007). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107, 103–111.
Lyytinen, H. K., Dyba, T., Ylikorkala, O., & Pukkala, E. I. (2010). A case‐control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. International Journal of Cancer, 126, 483–489.
Vinogradova, Y., Coupland, C., & Hippisley‐Cox, J. (2019). Use of hormone replacement therapy and risk of venous thromboembolism: Nested case‐control studies using the QResearch and CPRD databases. BMJ, 364, k4810. https://doi.org/10.1136/bmj.k4810
Scarabin, P.‐Y. (2018). Progestogens and venous thromboembolism in menopausal women: An updated oral versus transdermal estrogen meta‐analysis. Climacteric, 21, 341–345.
Chester, R. C., Kling, J. M., & Manson, J. E. (2018). What the Women's Health Initiative has taught us about menopausal hormone therapy. Clinical Cardiology, 41, 247–252.
Boardman, H. M. p., Hartley, L., Eisinga, A., Main, C., Roqué I Figuls, M., Bonfill Cosp, X., Gabriel Sanchez, R., & Knight, B. (2015). Hormone therapy for preventing cardiovascular disease in post‐menopausal women. Cochrane Database of Systematic Reviews, 2015, CD002229.
Hamoda, H., Mukherjee, A., Morris, E., Baldeweg, S. E., Jayasena, C. N., Briggs, P., & Moger, S. (2022). Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause. Post Reproductive Health, 28, 123–125.
NHS England. Shared decision‐making. https://www.england.nhs.uk/personalisedcare/shared‐decision‐making/
Theroux, R. (2010). Women's decision‐making during the menopausal transition. Journal of the American Academy of Nurse Practitioners, 22, 612–621.
Theroux, R., & Taylor, K. (2003). Women's decision‐making about the use of hormonal and nonhormonal remedies for the menopausal transition. Journal of Obstetric, Gynecologic & Neonatal Nursing, 32, 712–723.
Carpenter, J. S., Byrne, M. M., & Studts, J. L. (2011). Factors related to menopausal symptom management decisions. Maturitas, 70, 10–15.
O'connor, A. M., Tugwell, P., Wells, G. A., Elmslie, T., Jolly, E., Hollingworth, G., Mcpherson, R., Bunn, H., Graham, I., & Drake, E. (1998). A decision aid for women considering hormone therapy after menopause: Decision support framework and evaluation. Patient Education and Counseling, 33, 267–279.
Stacey, D., Légaré, F., Boland, L., Lewis, K. B., Loiselle, M. C., Hoefel, L., Garvelink, M., & O'connor, A. (2020). 20th Anniversary Ottawa Decision Support Framework: Part 3 Overview of Systematic Reviews and Updated Framework. Medical Decision‐making, 40, 379–398.
Harris, T. J., Cook, D. G., Wicks, P. D., & Cappuccio, F. P. (1999). Ethnic differences in use of hormone replacement therapy: Community based survey. BMJ, 319, 610–611.
Hunter, M. S., Gupta, P., Papitsch‐Clark, A., & Sturdee, D. W. (2009). Mid‐Aged Health in Women from the Indian Subcontinent (MAHWIS): A further quantitative and qualitative investigation of experience of menopause in UK Asian women, compared to UK Caucasian women and women living in Delhi. Climacteric, 12, 26–37.
Dotlic, J., Nicevic, S., Kurtagic, I., Radovanovic, S., Rancic, B., Markovic, N., Milosevic, B., & Gazibara, T. (2020). Hormonal therapy in menopausal transition: Implications for improvement of health‐related quality of life. Gynecological Endocrinology, 36, 327–332.
Mendoza, N., Hernández, C., Cornellana, M. J., Carballo, A., Llaneza, P., Harvey, X., & Palacios, S. (2016). Factors determining the use of hormonal therapy and phytotherapy in Spanish postmenopausal women. Climacteric, 19, 375–380.
Çilgin, H. (2019). Predictors of initiating hormone replacement therapy in postmenopausal women: A cross‐sectional study. Scientific World Journal, 2019, 1–8.
Torres, R. Y., & Marks, R. (2009). Relationships among health literacy, knowledge about hormone therapy, self‐efficacy, and decision‐making among postmenopausal health. Journal of Health Communication, 14, 43–55.
NHS Business Services Authority. (2023). Hormone Replacement Therapy—England—April 2015 to June 2023. https://www.nhsbsa.nhs.uk/statistical‐collections/hormone‐replacement‐therapy‐england/hormone‐replacement‐therapy‐england‐april‐2015‐june‐2023
Harper, J. C., Phillips, S., Biswakarma, R., Yasmin, E., Saridogan, E., Radhakrishnan, S., Davies, M. C., & Talaulikar, V. (2022). An online survey of perimenopausal women to determine their attitudes and knowledge of the menopause. Women's Health, 18, 1–18.
French, L. M., Smith, M. A., Holtrop, J. S., & Holmes‐Rovner, M. (2006). Hormone therapy after the Women's Health Initiative: A qualitative study. BMC Family Practice [Electronic Resource], 7, 61.
Hajjaj, F., Salek, M., Basra, M., & Finlay, A. (2010). Non‐clinical influences on clinical decision‐making: A major challenge to evidence‐based practice. Journal of the Royal Society of Medicine, 103, 178–187.
Franks, P., & Bertakis, K. D. (2003). Physician gender, patient gender, and primary care. Journal of Womens Health, 12, 73–80.
Bensing, J. M., Den Brink‐Muinen, A. V., & De Bakker, D. H. (1993). Gender differences in practice style. Medical Care, 31, 219–229.
Schumock, G. T., Walton, S. M., Park, H. Y., Nutescu, E. A., Blackburn, J. C., Finley, J. M., & Lewis, R. K. (2004). Factors that influence prescribing decisions. Annals of Pharmacotherapy, 38, 557–562.
Huston, S., Sleath, B., & Rubin, R. H. (2001). Physician gender and hormone replacement therapy discussion. Journal of Womens Health & Gender‐Based Medicine, 10, 279–287.
Dunne, F., Sadler, G., & Crampton, J. (1998). Hormone replacement therapy: Why are general practitioners not prescribing more? International Journal of Clinical Practice, 52, 285–288.
Levy, B. (2003). Physician specialty is significantly associated with hormone replacement therapy use. Obstetrics & Gynecology, 101, 114–122.
Hillman, S., Shantikumar, S., Ridha, A., Todkill, D., & Dale, J. (2020). Socioeconomic status and HRT prescribing: A study of practice‐level data in England. British Journal of General Practice, 70, e772–e777.
Newton, K. M., Lacroix, A. Z., Buist, D. S. M., Anderson, L. A., & Delaney, K. (2001). What factors account for hormone replacement therapy prescribing frequency? Maturitas, 39, 1–10.
Howard, S. (2022). GPs caught in media menopause spotlight. BMJ, 379, o2841. https://doi.org/10.1136/bmj.o2841
OpenPrescribing. 6.4.1: Female sex hormones and their modulators. https://openprescribing.net/bnf/060401/
Arseneau, M. E., Backonja, U., Litchman, M. L., Karimanfard, R., Sheng, X., & Taylor‐Swanson, L. (2021). #Menopause on Instagram: A mixed‐methods study. Menopause, 28, 391–399.
Kauffman, R. P., Maclaughlin, E. J., Courtney, L. A., & Vineyard, D. D. (2024). Fear, misinformation, and pharmaceutical messianism in the promotion of compounded bioidentical hormone therapy. Frontiers in Reproductive Health, 6, 1378644.
Yuksel, N., Treseng, L., Malik, B., & Ogbogu, U. (2017). Promotion and marketing of bioidentical hormone therapy on the internet: A content analysis of websites. Menopause, 24, 1129–1135.
Hamoda, H., Mukherjee, A., Morris, E., Baldeweg, S. E., Jayasena, C. N., Briggs, P., & Moger, S. (2022). Optimising the menopause transition: Joint position statement by the British Menopause Society, Royal College of Obstetricians and Gynaecologists and Society for Endocrinology on best practice recommendations for the care of women experiencing the menopause. Post Reproductive Health, 28, 121–122.
Constantine, G. D., Graham, S., Clerinx, C., Bernick, B. A., Krassan, M., Mirkin, S., & Currie, H. (2016). Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. Post Reproductive Health, 22, 112–122.
Hoffmann, M., Hammar, M., Kjellgren, K. I., Lindh‐Åstrand, L., & Ahlner, J. (2006). Risk communication in consultations about hormone therapy in the menopause: Concordance in risk assessment and framing due to the context. Climacteric, 9, 347–354.
An, A. H. R., Shin, D. W., Chun, S. H., Lee, H. K., Ko, Y. J., Lee, H., Son, K. Y., Choi, H. C., Cho, B., Lee, J. K., & Kim, J. G. (2014). Shared decision‐making on the use of hormone therapy: A nationwide survey in the Republic of Korea. Menopause, 21, 726–731.
Makoul, G., Arntson, P., & Schofield, T. (1995). Health promotion in primary care: Physician‐patient communication and decision‐making about prescription medications. Social Science & Medicine, 41, 1241–1254.
Dintakurti, N., Kalyanasundaram, S., Jha, P., & Talaulikar, V. (2022). An online survey and interview of GPs in the UK for assessing their satisfaction regarding the medical training curriculum and NICE guidelines for the management of menopause. Post Reproductive Health, 28, 137. https://doi.org/10.1177/20533691221106011
Walter, F. M., & Britten, N. (2002). Patients’ understanding of risk: A qualitative study of decision‐making about the menopause and hormone replacement therapy in general practice. Family Practice, 19, 579–586.
Welton, A., Hepworth, J., Collins, N., Ford, D., Knott, C., Meredith, S., Walgrove, A., Wilkes, H., & Vickers, M. (2004). Decision‐making about hormone replacement therapy by women in England and Scotland. Climacteric, 7, 41–49.
Hoffmann, M., Lindh‐Åstrand, L., Ahlner, J., Hammar, M., & Kjellgren, K. I. (2005). Hormone replacement therapy in the menopause. Maturitas, 50, 8–18.
Elwyn, G. (2006). Developing a quality criteria framework for patient decision aids: Online international Delphi consensus process. BMJ, 333, 417–420.
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes‐Rovner, M., Llewellyn‐Thomas, H., Lyddiatt, A., Thomson, R., & Trevena, L. (2017). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews, 2017, CD001431.
Department of Health and Social Care. (2022). Women's Health Strategy for England.
Office for National Statistics. (2021). Internet users. https://www.ons.gov.uk/businessindustryandtrade/itandinternetindustry/datasets/internetusers
Ghehi, L. M., Jafarabadi, M. A., Hakimi, S., Nourizadeh, R., Mehrabi, E., & Ebrahimpour, M. (2021). Menopausal Symptoms Management Decision Aid Trails: A Systematic Review and Meta‐analysis. International Journal of Women’s Health and Reproduction Sciences, 10(2), 71–78. https://doi.org/10.15296/ijwhr.2022.14